Skip to main content

Advertisement

Table 1 Characteristics of 12 children treated with GO.

From: Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia

Nr Age at diagnosis (yrs) Gender FAB Cytogenetic Features Molecular Biology WBC at diagnosis (.10 9 /L) WBC before GO (.10 9 /L) Nb of Relapses Treatment before relapse or GO
#1 1.8 M JMML N N 25.2 1.2 R Other
#2 1.1 M AML7 N N 23.0 5.0 1 CT♣
#3 1.1 F AML7 53,XX,+X,t(1;22)(p13;q13)+5,+6,+19,+20,+21 [18] OTT/MAL 9.0 8.2 2 CT♣ IL2 CB-SCT
#4 14.0 F AML1 47,XX,+8 [20] N 27.7 2.2 1 CT♣
#5 14.7 M MDS/AML6 N N 1.5 0.9 R CT♣ MUD-SCT
#6 17.2 F AML2 46,XX,t(6;9)(p23;q34) [25] DEK/CAN 3.3 10.9 1 CT♣
#7 2.8 M MDS/AML7 46,XY,del(3)(q24;q26) [6] N 11.4 22.0 R CT♣
#8 2.5 M AML7 N N 4.8 7.4 1 CT♣
#9 1.0 F AML7 46,t(2;16) [20] N 20.0 4.0 1 CT♣
#10 8.2 M AML5 46,XY,t(6;11)(q26;q23),del(12)(p11;p12) [17] N 38.0 0.2 1 CT♣
#11 13.5 M AML6 47,XY,del(3)(q23;qter), +8 [9] N 2.6 1.2 1 Other
#12 10.0 F AML2 45,XX,-7 [23] N 26.0 2.4 1 CT♣
  1. FAB indicates French-American-British classification; WBC, white blood cell; M, male; F, female; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplasia; AML, acute myeloblastic leukemia; N, normal; R, refractory; CB-SCT, cord blood-stem cell transplantation; IL2, interleukine 2; MUD-SCT, matched unrelated donor-stem cell transplantation.
  2. ♣ CT, chemotherapy according to national contemporary protocols (LAME 91, LAME 99, ELAM 02, EORTC 58921)